Published in Gene Therapy Weekly, June 13th, 2002
United States Patent No. 6,325,998 covers the use of recombinant AAV, free of both wild-type AAV and infectious helper virus, to deliver any therapeutic gene to muscle cells, including skeletal, smooth and cardiac muscle. United States Patent No. 6,335,011 covers methods for delivering genes via AAV to muscle tissue to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.